|
[1]
|
Use of Aerosolized Prostacyclins in Critically Ill Patients and Association With Clinical Outcomes
Critical Care Explorations,
2023
DOI:10.1097/CCE.0000000000000845
|
|
|
|
|
[2]
|
Use of Aerosolized Prostacyclins in Critically Ill Patients and Association With Clinical Outcomes
Critical Care Explorations,
2023
DOI:10.1097/CCE.0000000000000845
|
|
|
|
|
[3]
|
Use of Inhaled Epoprostenol in Patients With COVID-19 Receiving Humidified, High-Flow Nasal Oxygen Is Associated With Progressive Respiratory Failure
CHEST Critical Care,
2023
DOI:10.1016/j.chstcc.2023.100019
|
|
|
|
|
[4]
|
Evaluation of Inhaled Alprostadil in Hospitalized Adult Patients
Annals of Pharmacotherapy,
2022
DOI:10.1177/10600280211042675
|
|
|
|
|
[5]
|
Pharmacological management of adult patients with acute respiratory distress syndrome
Expert Opinion on Pharmacotherapy,
2020
DOI:10.1080/14656566.2020.1801636
|
|
|
|
|
[6]
|
Inhaled epoprostenol utilization pattern after implementation of an administration policy
Baylor University Medical Center Proceedings,
2020
DOI:10.1080/08998280.2019.1668668
|
|
|
|
|
[7]
|
COUNTERPOINT: Does Persistent or Worsening ARDS Refractory to Optimized Ventilation and Proning Deserve a Trial of Prostacyclin? No
Chest,
2019
DOI:10.1016/j.chest.2018.11.020
|
|
|
|
|
[8]
|
POINT: Does Persistent or Worsening ARDS Refractory to Optimized Ventilation and Proning Deserve a Trial of Prostacyclin? Yes
Chest,
2019
DOI:10.1016/j.chest.2018.11.018
|
|
|
|
|
[9]
|
Aerosolized prostacyclins for acute respiratory distress syndrome (ARDS)
Cochrane Database of Systematic Reviews,
2017
DOI:10.1002/14651858.CD007733.pub3
|
|
|
|
|
[10]
|
The Use of Inhaled Prostaglandins in Patients With ARDS
Chest,
2015
DOI:10.1378/chest.14-3161
|
|
|
|